Skip to main content
. Author manuscript; available in PMC: 2022 Dec 22.
Published in final edited form as: Clin Genitourin Cancer. 2021 Aug 16;20(2):97–101. doi: 10.1016/j.clgc.2021.08.001

Figure 1.

Figure 1

Best PSA and objective responses in mCRPC patients treated with BAT, stratified by mutational profile. (A) Twenty-two (22) mCRPC patients were observed to have a PSA decline of 70% or greater. Fifteen of the 15 patients with molecular testing information had a TP53 and/or HRD mutation (B) Best change in target lesions in 15 mCRPC patients with a deep PSA response on BAT is shown. Ten of 15 patients achieved an objective response on BAT. TP53 mutated – Red, HRD mutated – Blue, TP53/HRD mutated – Black, Unknown - White.